As the first study to show that miR‐21 promotes resistance to 5‐FU in pancreatic cancer cells by targeting PDCD4 and PTEN, our research demonstrates that a reduction in miR‐21 is critical to increase sensitivity to 5‐FU. Here, PTEN is linked to pancreatic neoplasm.